April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Rates of Functional Loss in Eyes With Progressive Optic Disc Damage
E. H. Leung; A. Tafreshi; P. A. Sample; L. M. Zangwill; R. N. Weinreb; F. A. Medeiros
Author Affiliations & Notes
  • E. H. Leung
    Ophthalmology, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California
  • A. Tafreshi
    Ophthalmology, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California
  • P. A. Sample
    Ophthalmology, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California
  • L. M. Zangwill
    Ophthalmology, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California
  • R. N. Weinreb
    Ophthalmology, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California
  • F. A. Medeiros
    Ophthalmology, Hamilton Glaucoma Center, University of California San Diego, La Jolla, California
  • Footnotes
    Commercial Relationships  E.H. Leung, None; A. Tafreshi, None; P.A. Sample, Carl Zeiss Meditec, Inc., F; Haag-Streit, F; Welch-Allyn, F; L.M. Zangwill, Carl Zeiss Meditec, Inc., F; Heidelberg Engineering, GmbH, F; Optovue, Inc., F; Topcon Medical Systems, Inc., F; R.N. Weinreb, Carl Zeiss Meditec, Inc., F; Heidelberg Engineering, GmbH, F; Novartis, F; Optovue, Inc., F; Topcon Medical Systems, Inc., F; Alcon Laboratories, Inc., C; Allergan, Inc., C; Carl Zeiss Meditec, Inc., C; Glaxo, C; Optovue, Inc., C; Pfizer, Inc., C; Topcon Medical Systems, Inc., C; F.A. Medeiros, Carl Zeiss Meditec, Inc., F; Alcon Laboratories, Inc., F; Pfizer, Inc., F; Alcon Laboratories, Inc., C; Allergan, Inc., C; Pfizer, Inc., C; Carl Zeiss Meditec, Inc., R; Alcon Laboratories, Inc., R; Allergan, Inc., R; Pfizer, Inc., R; Reichert, Inc., R.
  • Footnotes
    Support  NEI EY11008(LMZ), NEI EY08208(PAS), Allergan Horizon Grant(FAM), research grant from Pfizer(FAM), and glaucoma medication at no cost from Alcon Laboratories Inc, Allergan, Pfizer Inc, and Santen Inc.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4904. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Rates of Functional Loss in Eyes With Progressive Optic Disc Damage
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      E. H. Leung, A. Tafreshi, P. A. Sample, L. M. Zangwill, R. N. Weinreb, F. A. Medeiros; Rates of Functional Loss in Eyes With Progressive Optic Disc Damage. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4904.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To evaluate rates of functional loss as measured by standard automated perimetry (SAP) in eyes with progressive glaucomatous optic neuropathy (GON).

Methods: : The study included 639 eyes of 407 glaucoma suspect patients recruited from the Diagnostic Innovations in Glaucoma Study (DIGS) and followed for an average of 8.0 years with annual standard automated perimetry visual field and optic disc stereophotographs. Glaucoma suspects had suspicious appearance of the optic disc at baseline and/or history of elevated intraocular pressure (>21mmHg). All patients had normal and reliable SAP results at baseline. Presence of progressive GON was evaluated by grading longitudinally acquired simultaneous stereophotographs. Rates of progressive functional loss were evaluated using the Visual Field Index (VFI) of SAP. Random coefficients models were used to evaluate rates of progressive visual field loss in eyes with evidence of progressive GON compared to eyes without evidence of structural deterioration over time. Best linear unbiased prediction (BLUP) was used to estimate rates of change for individual eyes.

Results: : Ninety-six eyes (15%) had progressive GON during the follow-up period. The average rate of VFI loss in eyes with progressive GON was significantly greater than in eyes without optic disc change during follow-up (-0.63%/year versus -0.14%/year, respectively; P<0.001). However, there was a large variability in the rates of functional deterioration in eyes with progressive GON, with rates of VFI change ranging from 0.02%/year to -9.2%/year.

Conclusions: : Progressive glaucomatous optic neuropathy was associated with progressive functional deterioration. However, rates of functional loss were widely variable among eyes showing longitudinal evidence of structural change. Future studies will investigate risk factors for rapid structural or functional deterioration in glaucoma.

Keywords: clinical (human) or epidemiologic studies: biostatistics/epidemiology methodology • clinical (human) or epidemiologic studies: risk factor assessment • clinical (human) or epidemiologic studies: outcomes/complications 
© 2010, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept